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ORIGINAL ARTICLE
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ABSTRACT
Objective: We investigated the impact of multimorbidity and polypharmacy on the manage-
ment of atrial fibrillation (AF) patients in clinical practice and assessed factors associated with
polypharmacy and oral anticoagulation (OAC) use in AF patients with multimorbidity and
polypharmacy.
Methods: A 14-week prospective study of consecutive non-valvular AF patients was performed
in seven Balkan countries.
Results: Of 2712 consecutive patients, 2263 patients (83.4%) had multimorbidity (AF þ2 con-
comitant diseases) and 1505 patients (55.5%) had polypharmacy. 1416 (52.2%) patients had
both multimorbidity and polypharmacy. Overall, 1164 (82.2%) patients received OAC, 200
(14.1%) patients received antiplatelet drugs alone and 52 (3.7%) patients had no antithrombotic
therapy (AT). Non-emergency centre and paroxysmal AF were significantly associated with OAC
non-use in patients with multimorbidity, whilst age 80 years and non-emergency centre were
identified to be independent predictors of OAC non-use in patients with polypharmacy.
Conclusions: Multimorbidity and polypharmacy were common among AF patients in our study.
AT was suboptimal and approximately 18% of multimorbid patients with polypharmacy were
not anticoagulated. Pattern of AF and non-emergency centre were associated with OAC non-use
in AF patients with multimorbidity, whilst non-emergency centre and age 80 years were asso-
ciated with OAC non-use in AF patients with polypharmacy.
KEY MESSAGE
 Multimorbidity and polypharmacy are common among patients with AF.
 Antithrombotic therapy was suboptimal in AF patients with multimorbidity and
polypharmacy.
 Approximately, 18% of multimorbid patients with polypharmacy were not anticoagulated.
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Atrial fibrillation (AF) currently affects approximately
3% of adults worldwide [1,2], and patients with AF
often have multiple comorbidities [3]. Indeed, multi-
morbidity (i.e. the presence of two or more chronic
conditions) is common among patients with AF [4–7],
with hypertension, heart failure (HF), diabetes mellitus,
valvular heart disease, myocardial infarction (MI),
chronic obstructive pulmonary disease (COPD) and
chronic kidney disease (CKD) being the most prevalent
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comorbidities in AF patients [8]. Up to 50% of patients
with newly diagnosed AF have two or more concomi-
tant conditions, and these patients have greater stroke
and bleeding risks than non-multimorbid AF patients
[9,10]. Since stroke prevention is a cornerstone of opti-
mal AF management [11], it is critically important to
provide optimal antithrombotic therapy (AT) to
patients with AF and multimorbidity.
The number of concomitant diseases tends to be
directly related to polypharmacy (i.e. concomitant use
of five or more drugs regardless of the illness(es) they
have been prescribed for and their utility [12]).
Unsurprisingly, AF has been shown to be significantly
correlated with polypharmacy at the time of dis-
charge [13].
Studies assessing patients with AF and multimor-
bidity are scarce, and optimal management of patients
with AF and multimorbidity may be challenging for
physicians. The population of the Balkans (approxi-
mately 50 million inhabitants) was underrepresented
in the contemporary large international AF registries
[14], and data pertinent to the management of multi-
morbid AF patients in the Balkan region are lacking.
The BALKAN-AF survey recently provided insight into
contemporary management of AF patients in seven
Balkan countries [15,16].
In the present post hoc analysis of the BALKAN-AF
dataset, we investigated the impact of multimorbidity
and polypharmacy on the management of AF patients
in clinical practice and assessed factors associated
with polypharmacy and oral anticoagulation (OAC) use
in AF patients with multimorbidity and polypharmacy.
Materials and methods
The BALKAN-AF survey design has been previously
reported [14]. A 14-week prospective, multicentre
“snapshot” registry of consecutive patients with elec-
trocardiographically documented AF was designed by
the Serbian Atrial Fibrillation Association (SAFA) and
conducted from December 2014 to February 2015 in
collaboration with the National Cardiology Societies
and Associations or Working Groups in Albania, Bosnia
& Herzegovina, Bulgaria, Croatia, Montenegro,
Romania and Serbia. Patients treated by a cardiologist
or an internal medicine specialist, where cardiologist
was not available, were recruited by academic and
non-university hospitals and outpatient health centres
(a total of 49 centres). The centres were selected by
the respective National Coordinator. A signed patient
informed consent form was obtained before
enrolment. The study protocol is concordant with the
ethical guidelines of the 1975 Declaration of Helsinki.
The exclusion criteria were age <18 years and pros-
thetic mechanical heart valves or significant valvular
disease with indications for surgical repair.
Data were collected using an electronic case report
form (eCRF) designed by SAFA. The eCRF included
patient characteristics, patient presentation and
healthcare setting, diagnostic procedures undertaken
within the last 12 months and at enrolment and AF
management at enrolment and at discharge. Stroke
risk was estimated using the CHA2DS2-VASc (congest-
ive HF, hypertension, age  75 years, diabetes, stroke/
transient ischaemic attack (TIA), vascular disease, age
65–74 years, sex category) score [8]. Bleeding risk was
evaluated according to the HAS-BLED (hypertension,
abnormal renal/liver function, stroke, bleeding history
or predisposition, labile international normalized ratio
(INR), elderly (>65 years), drugs or alcohol concomi-
tantly) score [8,17]. All the cardiovascular risk factors,
diseases and risk scores definitions were defined
according to individual European Society of
Cardiology guidelines, other guidelines, scientific state-
ments and textbooks presented previously in supple-
mentary information [15].
Owing to the relatively short survey period, system-
atic monitoring of centres and follow-up visits were
not performed. National coordinators and investigators
were responsible for verification of the consecutive-
ness of enrolled patients and correctness and com-
pleteness of entered data.
Statistical analysis
Categorical variables were reported as absolute fre-
quencies and percentages, and continuous variables
as mean and standard deviation (SD). Comparison of
categorical variables with normal distribution was cal-
culated using Student’s t-test. Continuous variables
with skewed distribution were compared with
Mann–Whitney’s test. The descriptive analysis included
baseline characteristics of patients with/without multi-
morbidity and with/without polypharmacy. The varia-
bles with statistically significant association on
univariate logistic regression analysis were entered
into multivariable logistic regression models to identify
multivariable predictors of AF management. Results
are expressed as odds ratio with 95% confidence inter-
val. A two-sided p value of less than .05 was inter-
preted as statistically significant. All analyses were
performed using SAS software version 9.4 (SAS
Institute, Inc., Cary, NC).
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Results
Of 2712 consecutive patients, 2263 (83.4%) had multi-
morbidity, and polypharmacy was observed in 1505
patients (55.5%) (Supplementary Table 1 and Figure
1). Of the multimorbid patients, 1416 (62.6%) also had
polypharmacy, whilst 89 (19.8%) of non-multimorbid
individuals had polypharmacy.
Demographic and AF-related characteristics
Patients with multimorbidity were older, more often
female, less likely to have first-diagnosed or paroxys-
mal AF and more commonly had higher mean
European Heart Rhythm Association (EHRA) symptom
score and mean New York Heart Association (NYHA)
class (all p<.001) compared with non-multimorbid
patients. Similar findings were evident in patients with
polypharmacy versus those without polypharmacy (all
p<.001) (Supplementary Table 1).
Physical findings and comorbidity
Patients with multimorbidity had significantly higher
mean systolic blood pressure (SBP) and more comor-
bidities (both p<.05) than non-multimorbid AF
patients. Similar findings were evident in patients with
polypharmacy versus those without polypharmacy (all
p<.05) (Supplementary Table 1).
Stroke and bleeding risk factors
The mean CHA2DS2-VASc and HAS-BLED score values
were higher in multimorbid patients than in those
without multimorbidity (both p<.001) and the propor-
tion of patients with CHA2DS2-VASc score 2 and
HAS-BLED score 3 was higher in AF patients with
multimorbidity than in those without multimorbidity.
Similar findings were evident in patients with poly-
pharmacy versus those without polypharmacy (all
p<.001) (Supplementary Table 1).
Predictors of polypharmacy
On multivariate analysis, hypertension, HF, coronary
artery disease (CAD), MI, diabetes mellitus, aortic valve
disease, mitral valve disease and peripheral artery dis-
ease (PAD) were independent predictors of polyphar-
macy in patients with AF (Table 1).
AF management settings
Most participants were managed in an academic
healthcare facility. Patients with multimorbidity were
less often treated by cardiologist and AF was less
commonly the main reason for hospitalization com-
pared to non-multimorbid AF patients (both p<.05).
Patients with multimorbidity were more often hospi-
talized due to acute coronary syndromes (ACSs) and
HF than those without multimorbidity (both p<.05).
Individuals with polypharmacy were more often man-
aged by cardiologists, and AF was less commonly the
main reason for the hospitalization compared to
patients without polypharmacy (both p<.001). ACS, HF
and chronic coronary syndromes (CCSs) were also
Figure 1. Proportion of patients with AF according to number of comorbid diseases. AF: atrial fibrillation.
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more often reasons for the hospitalization compared
to those without polypharmacy (all p<.05) (Table 2).
Diagnostic assessment
Transthoracic echocardiography and cardiac computed
tomography were more often performed in patients with
multimorbidity compared to those without multimorbid-
ity (both p<.05). Cardiac catheterization was more often
performed in patients with polypharmacy compared to
than in those without polypharmacy (all p<.05) (Table 2).
Stroke prevention strategies
Overall, OACs alone or in combination with antiplate-
let (AP) drugs were used in 1686 (74.5%) of patients
with AF multimorbidity and in 279 (62.1%) of patients
without multimorbidity (p<.001). Patients with multi-
morbidity were more often prescribed VKA, aspirin
alone or in combination with OAC, dual AP therapy
alone, dual AT and triple AT (all p<.05) than patients
without multimorbidity. There were no significant dif-
ferences in the use of NOACs among multimorbid ver-
sus non-multimorbid patients and in patients with
versus those without polypharmacy. Multimorbid
patients were less likely to receive no AT than those
non-multimorbid (p<.001) (Table 2).
Overall, OAC alone or in combination with AP drugs
was used in 1242 (82.5%) of patients with AF and poly-
pharmacy and in 723 (59.9%) of those with AF without
polypharmacy (p<.001). Patients with polypharmacy
were more often prescribed VKA, aspirin alone or in
combination with OAC, dual and triple AT (all p  .001)
than patients without polypharmacy, see Table 2.
Arrhythmia-directed strategies
Rate control strategy was more frequently used in patients
with multimorbidity whereas rhythm control strategy was
more commonly used in patients without multimorbidity,
both p<.001. Patients with multimorbidity were less likely
to have AF catheter ablation or electric cardioversion
(both p<.05), more likely to use digoxin, calcium channel
blockers or beta-blockers (all p<.05) and less likely to
receive amiodarone or propafenone (both p<.05) than
those without multimorbidity. Rate control strategy,
digoxin, calcium channel blockers, beta blockers, propafe-
none and amiodarone were more frequently used in
patients with polypharmacy compared to individuals with-
out polypharmacy (all p<.05), see Table 2.
Other therapies
Multimorbid AF patients were more likely to receive
angiotensin-converting enzyme inhibitors (ACEi), AT1
receptor blockers, loop diuretics and statins, and poly-
pharmacy was more common among these patients
than in patients without multimorbidity (Table 2).
Similar findings were evident in patients with poly-
pharmacy versus those without polypharmacy (all
p<.001) (Table 2).
Characteristics of AF patients with both
multimorbidity and polypharmacy
AF patients with both multimorbidity and polyphar-
macy were older than those without multimorbidity
and polypharmacy (p<.001). They were less likely to
have first-diagnosed AF and paroxysmal AF than
patients without multimorbidity and polypharmacy
(both p<.001). They had higher mean EHRA symptom
score and mean NYHA class than those without multi-
morbidity and polypharmacy (both p<.001).
Patients with both multimorbidity and polyphar-
macy had higher mean CHA2DS2-VASc and mean HAS-
BLED score than individuals without multimorbidity
and polypharmacy (both p<.001). They were less likely
to be hospitalized because of AF than those without
multimorbidity and polypharmacy (p<.001)
(Supplementary Table 2).
Patients with both multimorbidity and polypharmacy
were more likely to be medicated with OAC alone or in
combination with AP agents, VKA, aspirin alone or with
OAC, dual and triple AT than those without multimor-
bidity and polypharmacy (all p<.001). They were also
more likely to receive rate control strategy, digoxin, cal-
cium channel blockers, amiodarone, ACEi, AT1 receptor
blockers, loop diuretics and statins than patients with-
out multimorbidity and polypharmacy (all p<.001)
(Supplementary Table 2).




OR 95% CI p Value
Hypertension 3.05 2.07–4.49 <.001
HF 2.12 1.78–2.52 <.001
CAD 2.53 2.11–3.04 <.001
MI 1.56 1.13–2.15 .007
Diabetes mellitus 2.24 1.84–2.72 <.001
Aortic valve disease 1.54 1.16–2.02 .002
Mitral valve disease 1.51 1.26–1.82 <.001
PAD 1.61 1.06–2.44 .024
AF: atrial fibrillation; CAD: coronary artery disease; CI: confidence interval;
HF: heart failure; MI: myocardial infarction: OR; odds ratio; PAD: peripheral
artery disease.
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Predictors of OAC use in patients with
multimorbidity
On multivariate analysis, age, a capital city-located
healthcare facility, structural heart diseases, diabetes
mellitus and rate control strategy were independent
predictors of OAC use, whereas non-emergency
centre and paroxysmal AF were significantly associated
with OAC non-use in patients with multimorbidity
(Table 3).













n¼ 1207 (44.5%) p Value
AF management settings, n (%)
Hospitalization due to AF 1006 (44.5) 331 (73.7) <.001 630 (41.9) 707 (58.6) <.001
Emergency hospitalization 1168 (51.6) 144 (32.1) <.001 788 (52.4) 523 (43.3) <.001
Hospitalization due to ACS 200 (8.8) 13 (2.9) <.001 173 (11.5) 39 (3.2) <.001
Hospitalization due to HF 652 (28.8) 12 (2.7) <.001 464 (30.8) 199 (16.5) <.001
Hospitalization due to CCS 107 (4.7) 24 (5.3) .578 86 (5.7) 45 (3.7) .017
Hospitalization due to hypertension 55 (2.4) 9 (2.0) .587 33 (2.2) 31 (2.6) .522
Outpatient visit 172 (7.6) 44 (9.8) .116 124 (8.2) 92 (7.6) .555
Academic healthcare facility 1804 (79.7) 357 (79.5) .312 1185 (78.7) 976 (80.9) .209
AF managed by cardiologist 1769 (78.2) 378 (84.2) .004 1216 (80.8) 931 (77.1) <.001
AF managed by internal
medicine specialist
360 (15.9) 47 (10.5) <.01 228 (19.1) 174 (14.4) <.001
AF managed by GP 48 (2.1) 16 (3.6) .073 24 (1.6) 33 (2.7) .153
AF managed by other specialist 86 (3.8) 8 (1.8) .057 40 (2.7) 51 (4.2) .319
Diagnostic assessment, n (%)
Routine biochemistry 1815 (80.2) 356 (79.3) .791 1210 (80.4) 961 (79.6) .257
Thyroid hormone measurement 761 (33.6) 182 (40.5) <.001 530 (35.2) 412 (34.1) .627
TTE 1817 (80.3) 330 (73.5) <.001 1219 (81.0) 927 (76.8) .208
Holter monitoring 585 (25.9) 123 (27.4) .094 397 (26.4) 311 (25.8) .580
Exercise stress test 139 (6.1) 34 (7.6) .111 101 (6.7) 72 (6.0) .929
Cardiac catheterization 277 (12.2) 44 (9.8) .364 233 (15.5) 88 (7.3) <.001
Cardiac CT scan 32 (1.4) 14 (3.1) .004 21 (1.4) 25 (2.1) .241
Stroke prevention, n (%)
No OAC 192 (8.5) 73 (16.3) <.001 55 (3.7) 210 (17.4) <.001
Overall OAC 1686 (74.5) 279 (62.1) <.001 1242 (82.5) 723 (59.9) <.001
OAC alone 1389 (61.4) 252 (56.1) .037 938 (62.3) 703 (58.2) <.001
Missing 3 (0.1) 21 (4.7) <.001 0 (0.0) 41 (3.4) <.001
VKA 1410 (62.3) 217 (48.3) <.001 1053 (70.0) 574 (47.6) <.001
NOAC 276 (12.2) 62 (13.8) .107 189 (12.6) 149 (12.3) .865
SAPT alone 269 (11.9) 52 (11.6) .667 141 (9.4) 180 (14.9) <.001
ASA (alone or with OAC) 604 (26.7) 84 (18.7) .007 447 (29.7) 241 (20.0) <.001
DAPT alone 113 (5.0) 7 (1.6) .003 67 (4.5) 53 (4.4) .908
Dual antithrombotic therapy 216 (9.5) 25 (5.6) .024 230 (15.3) 11 (0.9) <.001
Triple antithrombotic therapy 81 (3.6) 2 (0.4) .001 74 (4.9) 9 (0.7) <.001
Symptom management
AF catheter ablation 41 (1.8) 19 (4.2) <.001 28 (1.9) 32 (2.7) .064
ECV 69 (3.0) 28 (6.2) .001 50 (3.3) 47 (3.9) .168
AV node ablation with PM
implantation
7 (0.3) 3 (0.7) .130 6 (0.4) 4 (0.3)
Rate control 1464 (64.7) 158 (35.2) <.001 978 (65.0) 644 (53.4) <.001
Missing 32 (1.4) 34 (7.6) <.001 5 (0.3) 61 (5.1) <.001
Rhythm control 685 (30.3) 215 (47.9) <.001 482 (32.0) 418 (34.6) .152
Digoxin 620 (27.4) 35 (7.8) <.001 501 (33.3) 154 (12.8) <.001
Calcium channel blockers 122 (5.4) 8 (1.8) .001 448 (29.8) 94 (7.8) <.001
Beta blockers 1685 (74.5) 276 (61.5) <.001 1256 (83.5) 705 (58.4) <.001
Propafenone 161 (7.1) 85 (18.9) <.001 118 (7.8) 128 (10.6) .005
Flecainide 1 (0.0) 3 (0.7) .001 1 (0.1) 3 (0.2) .206
Sotalol 17 (0.8) 4 (0.9) .641 14 (0.9) 7 (0.6) .339
Amiodarone 542 (24.0) 120 (26.7) .024 435 (28.9) 227 (18.8) <.001
Other therapy, n (%)
ACEi 1108 (49.0) 156 (34.7) <.001 862 (57.3) 402 (33.3) <.001
AT1 receptor blockers 476 (21.0) 41 (9.1) <.001 384 (25.5) 133 (11.0) <.001
Loop diuretics 1079 (47.7) 41 (9.1) <.001 851 (56.5) 269 (22.3) <.001
Statins 1028 (45.4) 80 (17.8) <.001 880 (58.5) 228 (18.9) <.001
Polypharmacy 1416 (62.6) 89 (19.8) <.001
Number of drugs, mean (SD) 4.9 ± 1.5 3.4 ± 1.5 <.001 5.9 ± 0.9 4.0 ± 3.2 <.001
AF: atrial fibrillation; ACEi: angiotensin-converting enzyme inhibitors; ACS: acute coronary syndrome; ASA: acetylsalicylic acid; AV: atrioventricular; CCS:
chronic coronary syndrome; CT: computed tomography; DAPT: dual antiplatelet therapy; ECV: electrical cardioversion; GP: general practitioner; HF: heart
failure; NOAC: non-vitamin K oral anticoagulants; OAC: oral anticoagulation; PM: pacemaker; SAPT: single antiplatelet therapy; TTE: transthoracic echocar-
diography; VKA: vitamin K antagonists.p Values for patients with and without multimorbidity.p Values for patients with and without polypharmacy.
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Predictors of OAC use in patients with
polypharmacy
Whilst sharing the same multivariable predictors of
OAC use as in multimorbid patients, age 80 years
and non-emergency centre were identified to be inde-
pendent predictors of OAC non-use, whereas structural
heart disease and diabetes mellitus were independent
predictors of OAC use in patients with polypharmacy
(Table 3).
Characteristics of multimorbid patients with
newly-diagnosed AF or history of AF
Multimorbid patients with newly diagnosed AF had
higher mean EHRA symptom score than multimorbid
AF patients with history of AF (p<.05). They were less
likely to have previous stroke/TIA, HF, prior PCI/stent-
ing, DCM, mitral valve disease than multimorbid AF
patients with history of AF (all p<.05). Mean CHA2DS2-
VASc and HAS-BLED score values were lower in multi-
morbid patients with newly diagnosed AF than in mul-
timorbid patients with history of AF (both p<.05)
(Supplementary Table 6).
Predictors of OAC use in multimorbid patients
with newly diagnosed AF
Age, paroxysmal AF, CAD and MI were independent
predictors of OAC non-use in multimorbid patients
with newly diagnosed AF. Capital city, DCM, AF being
the main reason for the visit and rate control strategy
were independent predictors of OAC use in multimor-
bid patients with newly diagnosed AF (Supplementary
Table 7).
Discussion
Our study provides a novel data on “real-world” prac-
tice from the largest published prospective dataset
from the Balkan region which has been largely under-
represented in prior registries and reveals several
region-specific unmet needs and knowledge gaps
regarding management of AF patients with multimor-
bidity and polypharmacy.
In this study, multimorbidity was present in 83.4%
and polypharmacy was observed in 55.5% of the par-
ticipants. Several studies have demonstrated that AF
patients have significantly greater prevalence of con-
comitant diseases than age- and sex-matched controls
[5–7]. In our study, an average number of comorbid
conditions was lower than in a US study [6]. Our data
demonstrate that the prevalence of polypharmacy
among AF patients in the BALKAN-AF survey is high
and consistent with other studies [18,19]. Moreover,
approximately 20% of patients without multimorbidity
had polypharmacy, possibly owing to simultaneous
implementation of different treatment guidelines and
inappropriate drug prescriptions [20].
The main findings of our study were as follows: (i)
patients with both multimorbidity and polypharmacy
were older, more symptomatic and more likely to
have permanent AF, with higher stroke and bleeding
risk in comparison to those without multimorbidity or
polypharmacy, (ii) in multimorbid patients with poly-
pharmacy AF was less often the main reason for hos-
pitalization, but they more often received OAC (mostly
a VKA), aspirin (alone or with OAC), dual and triple AT,
and rate control strategy compared with patients with-
out multimorbidity or polypharmacy and (iii) the loca-
tion and type of healthcare facility, AF pattern and
structural heart disease significantly influenced the
stroke prevention strategies in AF patients with multi-
morbidity or polypharmacy.
The majority of AF multimorbid patients were pre-
scribed OAC (74.5%). About 20% of patients with mul-
timorbidity received SAPT only or no OAC despite
high risk of stroke and such patients should optimally
be anticoagulated. Optimal uptake of OAC includes
offering OAC to patients with 1 risk factors for
stroke, decision on OAC (an NOAC or a VKA with a
well-managed time in therapeutic range) and
patient involvement with shared decision making
Table 3. Independent predictors of OAC use in AF patients
with polypharmacy or multimorbidity.
OAC use in AF patients with multimorbidity
Multivariate analysis
OR 95% CI p Value
Age 1.16 1.08–1.24 <.001
Capital city 1.39 1.17–1.66 <.001
Non-emergency centre 0.52 0.41–0.65 <.001
Paroxysmal AF 0.47 0.40–0.57 <.001
Hypertension 3.49 2.84–4.29 <.001
HF 1.82 1.51–2.19 <.001
DCM 2.72 1.83–4.06 <.001
Diabetes mellitus 1.68 1.37–2.06 .001
Mitral valve diseasea 1.98 1.64–2.41 <.001
Rate control 1.82 1.54–2.15 <.001
OAC use in AF patients with polypharmacy
Non-emergency centre 0.68 0.56–0.83 <.001
Hypertension 3.51 2.85–4.43 <.001
Heart failure 1.86 1.56–2.21 <.001
CAD 2.73 2.25–3.31 <.001
DCM 1.97 1.40–2.77 <.001
Diabetes 2.05 1.65–2.55 <.001
Mitral valve diseasea 1.45 1.19–1.77 .001
Age  80 years 0.65 0.52–0.81 <.001
AF: atrial fibrillation; CAD: coronary artery disease; CI: confidence interval;
DCM: dilated cardiomyopathy; HF: heart failure; OAC: oral anticoagulants;
OR: odds ratio.
aMild to moderate regurgitation.
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[8,21]. Absolute contraindications to anticoagulation
are rare and complicated decisions including discon-
tinuation of OAC should be made by multidisciplinary
AF team.
The prescription of NOAC is reduced in patients
with multimorbidity or polypharmacy. Interestingly,
the decreased use of NOAC is also present in relatively
healthier AF patients with less prevalent comorbidities
in the BALKAN-AF study. The main reason for AP
drug(s) use was PCI, whereas the CHA2DS2-VASc risk
factors including hypertension, diabetes mellitus and
HF were independent predictors of OAC use in this
analysis. Mild-to-moderate mitral valve regurgitation
was also an independent predictor of OAC use in mul-
timorbid AF patients or those with polypharmacy,
whereas paroxysmal AF was significantly associated
with OAC non-use in multimorbid AF patients.
Notably, the use of OAC should be driven by the pres-
ence of CHA2DS2-VASc stroke risk factors, and the
temporal pattern of AF should not drive treatment
decisions about OAC use [21]. CAD and MI were asso-
ciated with decreased OAC use in multimorbid
patients with newly diagnosed AF in our study.
According to guidelines, OAC is indicated after elective
coronary stenting for stable CAD and after an ACS in
AF patients at risk of stroke [8]. Suboptimal OAC use
in patients with multimorbidity appears to be unmet
need in patients from BALKAN-AF survey. In one study
[22], the uncertainty on how to manage stroke risk
and use OAC in complex patients was one of the key
knowledge gaps. The location of healthcare centre in
capital city was associated with higher OAC use in
patients with multimorbidity in the BALKAN-AF survey.
The non-emergency centre was associated with lower
OAC use in AF patients with multimorbidity or poly-
pharmacy. In another study [23], OAC was more com-
monly prescribed in tertiary care centres (TCCs) which
are often situated in capital cities and adhere closely
to recommendations on stroke prevention in AF
patients [24].
In the Balkan region, factors other than evidence-
based medicine played an important role when decid-
ing whether to choose NOACs or VKAs. Possibly, VKAs
were better known to physicians than NOACs were.
Moreover, NOACs were not reimbursed in the partici-
pating countries (excluding Bulgaria) during the survey
period. Despite AF guidelines clearly indicate NOACs
over VKAs in most AF patients, the guidelines were
only modestly implemented in clinical practice in
Balkan countries [16]. Some multimorbid AF patients
may have contraindications to NOAC (e.g. those with
severely depressed renal function).
The underuse of OAC in patients aged  80 with
AF and polypharmacy may be related to the
concern of drug–drug interaction, adverse outcomes
or falls. However, stroke risk increases with age and
the absolute benefit of OAC is clearly increased as
the AF patients get older [25]. Importantly, NOACs
are associated with the best safety and efficacy
profiles compared to VKAs in very old patients
with non-valvular AF [26,27]. Our observations
emphasize the importance of reviewing drug regi-
mens for older persons with AF taking multiple
medications.
In our study, multimorbidity and polypharmacy
were associated with increased likelihood of rate con-
trol strategy. Interestingly, patients with multimorbid-
ity and polypharmacy were less likely to be treated
with amiodarone despite their more symptomatic sta-
tus and higher prevalence of HF than patients without
multimorbidity or polypharmacy.
Evidence from other studies reveals the high preva-
lence of polypharmacy in AF patients (40–64%)
[18,28,29]. Polypharmacy in AF patients reflects the
presence of multiple cardiovascular risk factors or
comorbidities. Moreover, polypharmacy and multimor-
bidity are associated with worse clinical outcome and
characterizes high-risk AF patients with many comor-
bid diseases [28,30]. The link between polypharmacy
and decreased adherence to medications, lower qual-
ity of life and delirium has also been reported [31].
NOACs should be preferred in AF patients with pol-
ypharmacy given their lower number of drug–drug
interactions compared with VKA [32,33]. No significant
difference regarding the use of NOACs in multimorbid
patients versus non-multimorbid patients and in
patients with polypharmacy versus those without poly-
pharmacy may be associated with low rate of NOAC in
our study, local reimbursement policies or drug avail-
ability in the market.
Patients with multimorbidity were less often hospi-
talized for AF and more often for other reasons than
patients without multimorbidity, thus reflecting a high
burden of comorbid conditions in multimorbid
patients. Importantly, most comorbid diseases in
patients with AF are associated with an increased risk
of hospitalization, and the risk is the highest in the
presence of HF and CKD [6]. In our study, manage-
ment in an academic healthcare facility may result in
the low incidence of first diagnosed AF or paroxysmal
AF. Management decisions seem to be influenced by
the type of care giver and early application of emerg-
ing treatment methods by academic healthcare
centres [23].
ANNALS OF MEDICINE 23
Single disease focus should be eliminated due to
high prevalence of multimorbidity and polypharmacy
in AF patients. Care givers should be aware, that mul-
timorbidity and polypharmacy in AF patients is associ-
ated with greater rates of adverse events and drug
interactions in those individuals. Integrated manage-
ment including patient involvement and shared deci-
sion making in multimorbid AF patients should be
implemented. Moreover, integrated care of AF patients
with multimorbidity should promote NOACs because
of their better safety profile in those patients.
Limitations
Our study is limited by its observational and snapshot
design. Since no follow-up was planned, there was no
evaluation of patient outcomes. Moreover, information
about patient/prescriber treatment preferences was
not available. Data on reasons for OAC non-prescrip-
tion were not reported. Physicians were aware that
their indications on treatment would be recorded, and
registries are likely to attract highly motivated subjects
and their medication at enrolment may reflect better
compliance. However, the enrolment of consecutive
patients limited the probability for investigators to
enrol mainly patients with higher compliance. This sur-
vey was limited to the inhabitants of the Balkans, but
it collected the largest AF dataset from this region,
which was largely underrepresented in contemporary
AF registries.
Conclusions
Multimorbidity and polypharmacy were common
among AF patients in our study. Antithrombotic ther-
apy was suboptimal (reduced prescription of OAC and
NOAC, high proportion of patients on AP alone or in
combination with OAC) and approximately 18% of
multimorbid patients with polypharmacy were not
anticoagulated. Pattern of AF and non-emergency
centre were associated with OAC non-use in AF
patients with multimorbidity, whilst age 80 years
and non-emergency centre were associated with OAC
non-use in AF patients with polypharmacy.
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